A Study of Sotorasib in People With Brain Metastases

Full Title

Purpose

Researchers are doing this study to see how well sotorasib gets into metastatic brain tumors. The people in this study have tumors in the brain that have spread there from other parts of the body. They are planning to have the brain metastases removed with surgery. In addition, their tumors have a mutation (change) in the KRAS gene (KRAS G12C+).

Sotorasib works by blocking the protein made by the mutated KRAS gene. Researchers think this drug may slow cancer growth or kill cancer cells. Sotorasib is taken orally (by mouth).

If you join this study, you will take sotorasib by mouth every day for 1 to 4 weeks leading up to your surgery. Your last dose of sotorasib will be about 1 hour before your surgery.

Who Can Join

To join this study, there are a few conditions. You must:

• Have KRAS G12C+ brain metastases that will be taken out with surgery.
• Have recovered from the serious side effects of prior anti-cancer therapies before taking sotorasib.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Nelson Moss’ office at 212-639-7075.